Key Takeaways
- • Private Swiss biotech funding reached a record CHF 946.4 million in 2026, representing a 25% increase above the previous 2020 peak, demonstrating pronounced strength in private capital deployment despite public market headwinds.
- • Basel-Stadt captured CHF 572 million of total private biotech funding, underscoring geographic concentration of venture and private equity capital in Switzerland's life sciences hub.
- • Private biotech revenues exceeded CHF 2 billion for the first time, while R&D investments grew to CHF 2.6 billion in 2024, indicating expanding operational scale and sustained research commitment despite sectoral financing challenges.
- • Public biotech financing remains constrained, with only one Swiss capital market transaction in 2024 (a reverse merger), while global biotech IPOs generated modest proceeds—highlighting the divergence between robust private funding and depressed public market access.
- • Total Swiss biotech capital investment reached CHF 2.5 billion in 2024, reflecting a 22% increase year-over-year and positioning private companies as the primary growth engine for the sector amid persistent public market volatility.
Summary
Private Swiss biotech companies are experiencing record-breaking funding momentum in 2026, sharply contrasting with a broader slowdown in public biotech financing. Private biotechs secured CHF 946.4 million in 2026—a 25% increase over the previous 2020 peak—demonstrating that institutional investors and venture capital are redirecting capital toward private structures as public market conditions deteriorate. This funding surge reflects a strategic reorientation within the Swiss life sciences ecosystem, where private capital has become the dominant force offsetting constrained public equity markets.
Basel-Stadt has emerged as the epicenter of this private funding wave, capturing CHF 572 million of total 2026 allocations. This geographic concentration underscores the critical importance of established life sciences clusters in attracting institutional capital, particularly as publicly traded biotech companies face sustained headwinds. The broader Swiss biotech sector raised CHF 2.5 billion in total capital investment during 2024, marking a 22% increase from the prior year and signaling investor confidence in the underlying pipeline despite macroeconomic challenges.
Private biotech firms are simultaneously expanding operational footprints and research intensity. Revenues in the sector surpassed CHF 2 billion for the first time, while R&D investment climbed to CHF 2.6 billion in 2024—a material increase from CHF 2.4 billion in 2023. This divergence between robust funding and constrained public markets reflects a structural bifurcation: private companies are scaling operations and research commitments, while public biotech access to capital markets remains severely limited. Switzerland recorded only one publicly traded biotech transaction in 2024 (a reverse merger), compared to global biotech IPO activity that generated modest proceeds of USD 4.0 billion across 30 transactions, with European biotech IPOs capturing just USD 0.3 billion.
The funding disparity reflects broader headwinds affecting publicly listed biotech firms, which are tightening investment discipline and forcing private investors to pursue alternative structures for capital deployment. This environment has positioned Swiss private biotech companies as attractive vehicles for institutional allocators seeking exposure to drug development and commercialization outside traditional public markets, while simultaneously supporting workforce expansion and R&D headcount growth in Switzerland's life sciences sector.
Basel-Stadt has emerged as the epicenter of this private funding wave, capturing CHF 572 million of total 2026 allocations. This geographic concentration underscores the critical importance of established life sciences clusters in attracting institutional capital, particularly as publicly traded biotech companies face sustained headwinds. The broader Swiss biotech sector raised CHF 2.5 billion in total capital investment during 2024, marking a 22% increase from the prior year and signaling investor confidence in the underlying pipeline despite macroeconomic challenges.
Private biotech firms are simultaneously expanding operational footprints and research intensity. Revenues in the sector surpassed CHF 2 billion for the first time, while R&D investment climbed to CHF 2.6 billion in 2024—a material increase from CHF 2.4 billion in 2023. This divergence between robust funding and constrained public markets reflects a structural bifurcation: private companies are scaling operations and research commitments, while public biotech access to capital markets remains severely limited. Switzerland recorded only one publicly traded biotech transaction in 2024 (a reverse merger), compared to global biotech IPO activity that generated modest proceeds of USD 4.0 billion across 30 transactions, with European biotech IPOs capturing just USD 0.3 billion.
The funding disparity reflects broader headwinds affecting publicly listed biotech firms, which are tightening investment discipline and forcing private investors to pursue alternative structures for capital deployment. This environment has positioned Swiss private biotech companies as attractive vehicles for institutional allocators seeking exposure to drug development and commercialization outside traditional public markets, while simultaneously supporting workforce expansion and R&D headcount growth in Switzerland's life sciences sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.